JP2003512354A - 非晶質アトルバスタチンカルシウムの製法 - Google Patents

非晶質アトルバスタチンカルシウムの製法

Info

Publication number
JP2003512354A
JP2003512354A JP2001531799A JP2001531799A JP2003512354A JP 2003512354 A JP2003512354 A JP 2003512354A JP 2001531799 A JP2001531799 A JP 2001531799A JP 2001531799 A JP2001531799 A JP 2001531799A JP 2003512354 A JP2003512354 A JP 2003512354A
Authority
JP
Japan
Prior art keywords
atorvastatin calcium
amorphous atorvastatin
amorphous
calcium
atorvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001531799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512354A5 (enExample
Inventor
グレフ ゾルターン
コータイ ナヂイ ペーター
バルコーツィ ヨージェフ
シミグ ヂューラ
バラージュ ラースロー
ドマーン イムレ
ラートカイ ゾルターン
セレシュ ペーター
セント キラールイ ジュジャーザ
バルタ フェレンツ
ヴェレツケイネー ドナート ヂョルヂー
ナヂー カールマーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Gyógyszergyár Zrt
Original Assignee
Egis Gyógyszergyár Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyógyszergyár Zrt filed Critical Egis Gyógyszergyár Zrt
Publication of JP2003512354A publication Critical patent/JP2003512354A/ja
Publication of JP2003512354A5 publication Critical patent/JP2003512354A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2001531799A 1999-10-18 2000-10-17 非晶質アトルバスタチンカルシウムの製法 Pending JP2003512354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9903634 1999-10-18
HU9903634A HU226640B1 (en) 1999-10-18 1999-10-18 Process for producing amorphous atorvastatin calcium salt
PCT/HU2000/000106 WO2001028999A1 (en) 1999-10-18 2000-10-17 Process for the preparation of amorphous atorvastatin calcium

Publications (2)

Publication Number Publication Date
JP2003512354A true JP2003512354A (ja) 2003-04-02
JP2003512354A5 JP2003512354A5 (enExample) 2005-04-21

Family

ID=90014241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001531799A Pending JP2003512354A (ja) 1999-10-18 2000-10-17 非晶質アトルバスタチンカルシウムの製法

Country Status (17)

Country Link
EP (1) EP1235800B1 (enExample)
JP (1) JP2003512354A (enExample)
KR (1) KR100664353B1 (enExample)
CN (1) CN1157374C (enExample)
AT (1) ATE345327T1 (enExample)
AU (1) AU1166301A (enExample)
CA (1) CA2388018C (enExample)
CZ (1) CZ300071B6 (enExample)
DE (1) DE60031882T2 (enExample)
HR (1) HRP20020334B1 (enExample)
HU (1) HU226640B1 (enExample)
PL (1) PL354604A1 (enExample)
RS (1) RS50473B (enExample)
RU (1) RU2255932C2 (enExample)
SK (1) SK286861B6 (enExample)
UA (1) UA72777C2 (enExample)
WO (1) WO2001028999A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515430A (ja) * 2004-10-18 2007-06-14 テバ ファーマシューティカル インダストリーズ リミティド アルコール及びケトン、及び／又はエステルの混合物である有機溶媒に塩を溶解し、そして溶媒を除去することにより非晶質アトルバスタチンへミ−カルシウムの調製方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
DE10135493A1 (de) * 2001-07-20 2003-01-30 Jobst Krauskopf Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie
JP2005500351A (ja) 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
EP1485343B1 (en) * 2002-03-18 2009-12-23 Biocon Limited Amorphous hmg-coa reductase inhibitors of desired particle size
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
JP2007532622A (ja) * 2004-04-16 2007-11-15 ファイザー・プロダクツ・インク 非晶質アトルバスタチン・カルシウムの形成方法
CN1692906A (zh) * 2004-04-30 2005-11-09 鲁南制药集团股份有限公司 治疗高血脂症的组合物
EP3581564A1 (en) 2004-05-05 2019-12-18 Pfizer Products Inc. Diethylamine salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
TW200825092A (en) * 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0358967A (ja) * 1989-07-21 1991-03-14 Warner Lambert Co 〔Ｒ―（Ｒ‖，Ｒ‖）〕―２―（４―フルオロフエニル）―β，δ―ジヒドロキシ―５―（１―メチルエチル）―３―フエニル―４―〔（フエニルアミノ）カルボニル〕―１Ｈ―ピロール―１―ヘプタン酸、そのラクトン体およびその塩
WO1998012200A1 (en) * 1996-09-20 1998-03-26 Meiji Seika Kaisha Ltd. A crystalline substance of cefditoren pivoxyl and the production of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2072468T3 (es) * 1990-05-11 1995-07-16 American Cyanamid Co Nuevos arilpirroles n-acilados utiles como agentes insecticidas, acaricidas, nematicidas y molusquicidas.
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0358967A (ja) * 1989-07-21 1991-03-14 Warner Lambert Co 〔Ｒ―（Ｒ‖，Ｒ‖）〕―２―（４―フルオロフエニル）―β，δ―ジヒドロキシ―５―（１―メチルエチル）―３―フエニル―４―〔（フエニルアミノ）カルボニル〕―１Ｈ―ピロール―１―ヘプタン酸、そのラクトン体およびその塩
WO1998012200A1 (en) * 1996-09-20 1998-03-26 Meiji Seika Kaisha Ltd. A crystalline substance of cefditoren pivoxyl and the production of the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515430A (ja) * 2004-10-18 2007-06-14 テバ ファーマシューティカル インダストリーズ リミティド アルコール及びケトン、及び／又はエステルの混合物である有機溶媒に塩を溶解し、そして溶媒を除去することにより非晶質アトルバスタチンへミ−カルシウムの調製方法

Also Published As

Publication number Publication date
HK1050199A1 (en) 2003-06-13
KR20020063166A (ko) 2002-08-01
DE60031882D1 (de) 2006-12-28
HRP20020334A2 (en) 2004-02-29
WO2001028999A1 (en) 2001-04-26
HUP9903634A2 (hu) 2001-12-28
CN1157374C (zh) 2004-07-14
PL354604A1 (en) 2004-01-26
EP1235800A1 (en) 2002-09-04
HUP9903634D0 (en) 1999-12-28
SK286861B6 (sk) 2009-06-05
RS50473B (sr) 2010-03-02
CA2388018A1 (en) 2001-04-26
CA2388018C (en) 2008-04-08
AU1166301A (en) 2001-04-30
ATE345327T1 (de) 2006-12-15
SK5192002A3 (en) 2002-11-06
KR100664353B1 (ko) 2007-01-02
HU226640B1 (en) 2009-05-28
UA72777C2 (en) 2005-04-15
CN1379760A (zh) 2002-11-13
RU2255932C2 (ru) 2005-07-10
YU28302A (sh) 2005-06-10
HRP20020334B1 (hr) 2007-12-31
HUP9903634A3 (en) 2002-01-28
CZ20021256A3 (cs) 2002-08-14
DE60031882T2 (de) 2007-07-05
EP1235800B1 (en) 2006-11-15
CZ300071B6 (cs) 2009-01-21

Similar Documents

Publication Publication Date Title
CA2388018C (en) Process for the preparation of amorphous atorvastatin calcium
JP2009221216A (ja) アトルバスタチン結晶体
JP2002519422A (ja) パロキセチンメタンスルホネート
US6646133B1 (en) Process for the preparation of amorphous atorvastatin calcium
IL148050A (en) Crystals of the sodium salt of pravastatin
AU2002330735A1 (en) Atorvastatin calcium form vi or hydrates thereof
EP1608618A1 (en) Process for the synthesis of amorphous atorvastatin calcium
JP6894489B2 (ja) ベラプロスト−３１４ｄ・一水和物結晶及びその製造方法
EP1732886B1 (en) Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin
JP2002522417A (ja) ゾフェノプリルカルシウム塩の調製方法
JP2002512223A (ja) 純粋な鏡像体であるｎ−メチル−ｎ−［（１ｓ）−１−フェニル−２−（（３ｓ）−３−ヒドロキシピロリジン−１−イル）エチル］−２，２−ジフェニルアセトアミドの製造方法
US20040063969A1 (en) Process for the preparation of amorphous atorvastatin calcium
WO2007132472A1 (en) A crystalline form b4 of atorvastatin magnesium and a process thereof
EP1979313A1 (en) Process for the preparation of amorphous atorvastatin calcium salt
CN1902194B (zh) 制备非晶态(4r-顺)-6-[2-[3-苯基-4-(苯基氨基甲酰基)-2-(4-氟苯基)-5-(1-甲基乙基)-吡咯-1-基]-乙基]-2,2-二甲基-[1,3]-二噁烷-4-基-乙酸的方法
WO2005073187A1 (en) Improved process for the preparation of amorphous atorvastatin calcium
HK1050199B (en) Process for the preparation of amorphous atorvastatin calcium
US20120046335A1 (en) Solid states of atorvastatin potassium
WO2006048888A1 (en) Novel process for the preparation of amorphous atorvastatin calcium salt
WO2005033078A1 (en) Process for the production of atorvastatin calcium
JP2002533458A (ja) パロキセチン酢酸塩またはパロキセチンアナログの製造方法
JP2002533441A (ja) 酢酸パロキセチンおよびそのアナログの製造法
JP2002533459A (ja) パロキセチン酢酸塩またはパロキセチンアナログの製造方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110426